Jakafi (ruxolitinib phosphate) Tablet
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
March 2016
WARNINGS AND PRECAUTIONS
Risk of Infection
Hepatitis B: Hepatitis B viral load (HBV-DNA titer) increases, with or...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts